We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

More feathers

13 February 2013 By Robert Cyran

Pharma mergers are usually a recipe for destroyed value. Yet big drugs companies need the innovation more prevalent at biotech firms. Sanofi’s increased stake in the $16 bln Regeneron, avoiding full control, is a good way to collect feathers without swallowing the bird.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)